BioCentury
ARTICLE | Company News

Chugai, Taisho Pharmaceutical Holdings sales and marketing update

September 9, 2013 7:00 AM UTC

Chugai and Taisho launched monthly IV Bonviva ibandronate in Japan to treat osteoporosis. The product has a Japanese National Health Insurance (NHI) list price of ¥4,918 ($49.92) per 1 mg syringe, the recommended monthly dose. Chugai partnered with Taisho in 2006 to co-develop and co-market in Japan the bisphosphonate that inhibits osteoclast-mediated bone resorption. The partners are developing a monthly oral formulation, which is in Phase III testing. Chugai is majority owned by Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) (see BioCentury, Sept. 18, 2006). ...